百蕊颗粒抗小鼠流感病毒性肺炎作用及机制研究

doi:10.19803/j.1672-8629.20230321

中国药物警戒 ›› 2023, Vol. 20 ›› Issue (11): 1249-1255.
DOI: 10.19803/j.1672-8629.20230321

百蕊颗粒抗小鼠流感病毒性肺炎作用及机制研究

邓玉荣¹, 孙建辉¹, 郝莉雨¹, 单中超^1,2, 于泽玥¹, 李建良¹, 霍海如¹, 李绮婧³, 张宏萌^3#, 李洪梅^1,*

¹中国中医科学院中药研究所,北京 100700;
²江西中医药大学院士工作站,江西南昌 330004;
³山东中医药大学,山东济南 250355

收稿日期:2023-05-22 出版日期:2023-11-15 发布日期:2023-11-13
通讯作者: ^*李洪梅,女,博士,研究员·博导,中药药理研究及新药开发。E-mail: lihm2006@sina.cn,^#为共同通信作者。
作者简介:邓玉荣,女,本科,中药药理。
基金资助:
国家重点研发计划（2022YFC0867600）; 中国中医科学院科技创新工程重大攻关项目（CI2021A04605）; 中国中医科学院科技创新工程创新团队项目（CI2021B015）; 中国中医科学院中央级公益性科研院所基本科研业务费(ZZ15-WT-04、ZZ15-WT-08)

Therapeutic effect and mechanism of Bairui granules against influenza virus-induced viral pneumonia in mice

DENG Yurong¹, SUN Jianhui¹, HAO Liyu¹, SHAN Zhongchao^1,2, YU Zeyue¹, LI Jianliang¹, HUO Hairu¹, LI Qijing³, ZHANG Hongmeng^3#, LI Hongmei^1,*

¹Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing 100700, China;
²Academician Workstation of Jiangxi University of Traditional Chinese Medicine, Nanchang Jiangxi 330004, China;
³Shandong University of Traditional Chinese Medicine, Ji’nan Shandong 250355, China

Received:2023-05-22 Online:2023-11-15 Published:2023-11-13

摘要/Abstract

摘要： 目的研究百蕊颗粒对流感病毒致小鼠病毒性肺炎的影响及可能作用机制。方法将ICR小鼠按体重随机分组,分别为正常对照组,模型对照组,百蕊颗粒18.84、9.42、4.71 g·kg^-1组,阳性对照药磷酸奥司他韦胶囊组。除正常对照组外,其余各组小鼠滴鼻感染流感病毒构建小鼠病毒性肺炎模型,测定小鼠的存活时间、死亡率;并测定病毒感染不同阶段（感染3、5、7 d后）正常对照组、模型对照组、百蕊颗粒18.84 g·kg^-1组、磷酸奥司他韦胶囊组小鼠的体重、肺指数、肺组织病毒载量、血清炎症因子[白细胞介素-6（IL-6）、γ-干扰素（IFN-γ）、肿瘤坏死因子-α（TNF-α）]水平。结果甲型流感病毒感染小鼠后,与正常对照组相比,模型对照组小鼠体重下降,肺指数、肺组织病毒载量、血清炎症因子水平升高,表明流感病毒性肺炎模型成立;与模型对照组相比,百蕊颗粒18.84、9.42、4.71 g·kg^-1组存活时间明显延长（P<0.01）,死亡率明显降低（P<0.01）,感染5、7 d后百蕊颗粒18.84 g·kg^-1组小鼠体重显著升高（P<0.05）,感染3、5、7 d后百蕊颗粒18.84 g·kg^-1组小鼠肺指数值显著降低（P<0.05）;感染5 d后百蕊颗粒18.84 g·kg^-1组病毒载量较模型组明显降低（P<0.01）,感染7 d后百蕊颗粒18.84 g·kg^-1组血清IL-6含量较模型对照组显著降低（P<0.01）。结论百蕊颗粒对流感病毒感染致小鼠病毒性肺炎具有治疗作用,可提高病毒感染小鼠体重、降低肺指数,延长病毒感染小鼠存活时间、降低死亡率,其可能是通过降低肺组织病毒载量、血清炎症因子含量发挥抗流感作用。

关键词: 百蕊颗粒, 流感病毒性肺炎, 死亡保护, 炎症因子, 病毒载量, 小鼠

Abstract: Objective To study the therapeutic effect and mechanism of Bairui granules against influenza virus-induced viral pneumonia in mice. Methods According to body weight, ICR mice were randomly divided into groups: the normal control group, model control group, Bairui granules 18.84、9.42、4.71 g·kg^-1 groups, and the positive control oseltamivir phosphate capsule group. Except the normal control group, all these groups of mice were intranasally infected with influenza virus to establish a mouse model of viral pneumonia. The survival and mortality of the mice were observed. Furthermore, the body weight, lung index, viral load in lung tissue, and serum levels of inflammatory factors interleukin-6 (IL-6), γ-interferon (IFN-γ), and tumor necrosis factor-α (TNF-α) at 3, 5 and 7 days post infection (dpi) were measured in the normal control group, model control group, Bairui granules 18.84 g·kg^-1 group and oseltamivir phosphate capsule group. Results Compared with the normal control group, the mice infected with influenza A virus showed a decrease in weight but an increase in the lung index, viral load in lung tissue, and the levels of serum inflammatory factors, indicating that a mouse model for influenza virus pneumonia was established. Compared with the model control group, the Bairui granules 18.84, 9.42, 4.71 g·kg^-1 groups showed a significant prolongation in survival time (P<0.01) and a significant decrease in mortality after being infected by influenza virus (P<0.01). In addition, the Bairui granules 18.84 g·kg^-1 group exhibited a significant increase in body weight (P<0.05) at 5 and 7 dpi, and a significant decrease in the lung index (P<0.05) at 3,5 and 7 dpi. Moreover, the viral load in the Bairui granules 18.84 g·kg^-1group was significantly lower than that of the model control group (P<0.01) at 5 dpi, and the serum IL-6 content in the Bairui granules 18.84 g·kg^-1 group was significantly lower than that of the model control group (P<0.01) at 7 dpi. Conclusion Bairui granules show some therapeutic effect against viral pneumonia in mice induced by influenza virus infection by increasing body weight, decreasing the lung index, prolonging survival, and reducing mortality in virus-infected mice.

Key words: Bairui granules, influenza virus pneumonia, death protection, inflammatory factors, viral load, mice

中图分类号:

R971
R744

邓玉荣, 孙建辉, 郝莉雨, 单中超, 于泽玥, 李建良, 霍海如, 李绮婧, 张宏萌, 李洪梅. 百蕊颗粒抗小鼠流感病毒性肺炎作用及机制研究[J]. 中国药物警戒, 2023, 20(11): 1249-1255.

DENG Yurong, SUN Jianhui, HAO Liyu, SHAN Zhongchao, YU Zeyue, LI Jianliang, HUO Hairu, LI Qijing, ZHANG Hongmeng, LI Hongmei. Therapeutic effect and mechanism of Bairui granules against influenza virus-induced viral pneumonia in mice[J]. Chinese Journal of Pharmacovigilance, 2023, 20(11): 1249-1255.

参考文献

[1] CACERES CJ, SEIBERT B, CARGNIN FF, et al.Influenza antivirals and animal models[J]. FEBS Open Bio, 2022, 12(6): 1142-1165.
[2] KISSLING E, ROSE A, EMBORG HD, et al.Interim 2018/19 influenza vaccine effectiveness: six European studies, October 2018 to January 2019[J]. Euro Surveill,2019,24(8):1900121.
[3] YI N.Advances in anti-influenza virus effects of traditional Chinese medicine[J]. Heilongjiang Medicine Journal(黑龙江医药), 2021, 34(2): 306-308.
[4] LIAO YY, ZHOU GQ.Research progress in clinical application of Bailui granules[J]. Journal of Modern Medicine & Health(现代医药卫生), 2021, 37(7): 1149-1152.
[5] ZHU MW, MA WX.Therapeutic effect of Bailiu granules combined with ribavirin in the treatment of seasonal influenza in children[J]. China Pharmacist(中国药师), 2015, 18(8): 1343-1345.
[6] PAN YP.Effect of oseltamivir phosphate combined with Balui granules in the treatment of influenza in children[J]. Strait Pharmaceutical Journal(海峡药学), 2021, 33(8): 113-115.
[7] CHEN Q.Research Methodology of TCM Pharmacology(中药药理研究方法学)[M]. Beijing: People’s Medical Publishing House, 2006.
[8] SUN JH, TANG CY, HUO HR, et al.Protective effect of Houyanqing extract on pneumonia mice model infected with influenza virus[J]. Central South Pharmacy(中南药学), 2019, 17(8): 1229-1233.
[9] MENG QY.Basic Theoretical Research Methods and Experimental techniques of Integrated Chinese and Western Medicine[M]. Beijing: Ancient Books of Traditional Chinese Medicine Publishing House, 1999.
[10] BAO L, GENG ZH, GUO SS, et al.Effect of Reyanning Heji on animal models of respiratory infectious inflammation[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2023, 20(3): 241-247.
[11] YAO RM, MAO X, QU TG, et al.Effect of Chuankezhi injection on prevention and treatment of H1N1 influenza virus in mice[J]. Chinese Journal of Experimental Traditional Medical Formulae(中国实验方剂学杂志), 2019, 25(12): 43-49.
[12] LI Z, LI L, ZHAO S, et al.Re-understanding anti-influenza strategy: attach equal importance to antiviral and anti-inflammatory therapies[J]. Journal of Thoracic Disease, 2018, 10(Suppl 19): 2248-2259.
[13] GIANNELLA M, ALONSO M, GARCIA DE VD, et al.Prolonged viral shedding in pandemic influenza A(H1N1): clinical significance and viral load analysis in hospitalized patients[J]. Clinical Microbiology and Infection, 2011, 17(8): 1160-1165.
[14] SONG LS, ZHANG XM, GUO QS, et al.Study on winter dormancy of Thesium chinense and its phenological phase[J]. China Journal of Chinese Materia Medica(中国中药杂志), 2015, 40(23): 4585-4590.
[15] ZOU Y, HONG M, YANG XF.Isolation of chemical components from thesium Chinense[J]. Chinese Journal of Experimental Traditional Medical Formulae(中国实验方剂学杂志), 2016, 22(7): 74-77.
[16] CHEN PY, CHEN XQ, WU C, et al.Research on development and utilization of thesium Chinense turcz[J]. Chinese Wild Plant Resources(中国野生植物资源), 2020, 39(6): 48-52.
[17] GUO AL, ZHU WW, ZHU J, et al.Clinical observation on the treatment for bronchiolitis in children with Bairui granules and atomization[J]. Chinese Pediatrics of Integrated Traditional and Western Medicine(中国中西医结合儿科学),2017, 9(1): 46-48.
[18] MURDACA G, PALADIN F, TONACCI A, et al.The potential role of cytokine storm pathway in the clinical course of viral respiratory pandemic[J]. Biomedicines, 2021, 9(11): 1688.
[19] LIU Q, ZHOU Y, YANG Z.The cytokine storm of severe influenza and development of immunomodulatory therapy[J]. Cellular & Molecular Immunology, 2016, 13(1): 3-10.
[20] BERMEJO-MARTIN JF, ORTIZ DE LR, PUMAROLA T, et al.Th1 and Th17 hypercytokinemia as early host response signature in severe pandemic influenza[J]. Critical Care (London, England), 2009, 13(6): R201.
[21] BETAKOVA T, KOSTRABOVA A, LACHOVA V, et al.Cytokines induced during influenza virus infection[J]. Current Pharmaceutical Design, 2017, 23(18): 2616-2622.
[22] PANDEY P, KARUPIAH G.Targeting tumour necrosis factor to ameliorate viral pneumonia[J]. The FEBS Journal, 2022, 289(4): 883-900.
[23] PEPER RL, VAN CAMPEN H.Tumor necrosis factor as a mediator of inflammation in influenza a viral pneumonia[J]. Microbial Pathogenesis, 1995, 19(3): 175-183.
[24] FRITZ RS, HAYDEN FG, CALFEE DP, et al.Nasal cytokine and chemokine responses in experimental influenza a virus infection: results of a placebo-controlled trial of intravenous zanamivir treatment[J]. The Journal of Infectious Diseases, 1999, 180(3): 586-593.
[25] HAGAU N, SLAVCOVICI A, GONGANAU DN, et al.Clinical aspects and cytokine response in severe H1N1 influenza a virus infection[J]. Critical Care (London, England), 2010, 14(6): R203.

百蕊颗粒抗小鼠流感病毒性肺炎作用及机制研究

Therapeutic effect and mechanism of Bairui granules against influenza virus-induced viral pneumonia in mice

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	孙绮悦, 赵荣华, 包蕾, 郭姗姗, 耿子涵, 李舒冉, 徐英莉, 张敬升, 崔晓兰, 孙静. 基于多动物模型药效评价体系研究羚羊感冒口服液儿童用药剂量[J]. 中国药物警戒, 2024, 21(2): 121-126.
[2]	孙绮悦, 赵荣华, 郭姗姗, 包蕾, 耿子涵, 李舒冉, 徐英莉, 张敬升, 崔晓兰, 孙静. 羚羊感冒口服液多重药理作用研究[J]. 中国药物警戒, 2024, 21(2): 127-131.
[3]	赵荣华, 孙静, 包蕾, 耿子涵, 陶夏莉, 张敬升, 庞博, 徐英莉, 曹姗, 李舒冉, 郭姗姗, 王道涵, 崔晓兰. 基于免疫调节探讨葛根汤颗粒治疗小鼠病毒性肺炎的作用机制[J]. 中国药物警戒, 2024, 21(2): 132-136.
[4]	曹姗, 庞博, 徐英莉, 张敬升, 陈梦苹, 张宇, 王雅欣, 包蕾, 耿子涵, 郭姗姗, 赵荣华, 崔晓兰. 疏风解毒胶囊预防给药对流感病毒感染小鼠模型TLR4介导肺组织炎性损伤的影响[J]. 中国药物警戒, 2024, 21(1): 45-50.
[5]	张敬升, 高双荣, 庞博, 刘莉娜, 徐英莉, 曹姗, 陈梦苹, 张宇, 赵荣华, 崔晓兰. 散寒化湿颗粒对人冠状病毒229E和OC43感染致小鼠肺炎的作用机制研究[J]. 中国药物警戒, 2024, 21(1): 51-54.
[6]	张亮亮, 胡昌坤, 吴泽坤, 周维, 廖泽彬, 高月. 富马酸二甲酯对肠道辐射损伤防护作用及机制研究[J]. 中国药物警戒, 2024, 21(1): 83-88.
[7]	殷玉玲, 胡楚涓, 张晓朦, 王雨, 张冰, 林志健. 菊苣提取物抗阿霉素心脏毒性作用挖掘及验证[J]. 中国药物警戒, 2023, 20(8): 858-865.
[8]	梅雨, 朱越, 张慧婷, 肖成荣, 高月, 马增春. 基于网络药理学和实验验证探讨中药复方CB001对低剂量辐射防护的作用机制[J]. 中国药物警戒, 2023, 20(8): 872-879.
[9]	杨明翰, 乔美玲, 骆骄阳, 杨美华, 盛萍. 多伞阿魏抗胃癌活性部位的急性毒性试验研究[J]. 中国药物警戒, 2023, 20(8): 880-884.
[10]	沈宁宁, 刘昱甫, 茹毅, 师卓, 杨春启, 倪喆鑫, 肖成荣, 马增春, 王宇光, 高月. 麦冬皂苷D对小鼠力竭游泳抗疲劳作用的研究[J]. 中国药物警戒, 2023, 20(7): 749-753.
[11]	王荣, 刘自群, 王娜娜, 谭雄, 张怡心, 杨宽, 秦蓓. 脯氨酸丹参素冰片酯对小鼠急性毒性研究[J]. 中国药物警戒, 2023, 20(7): 754-757.
[12]	左泽平, 田颖颖, 徐意, 姜克武, 杨硕, 杨海润, 张志聪, 曹欣垚, 吴笑如, 王志斌. 金匮肾气丸临床前安全性评价研究[J]. 中国药物警戒, 2023, 20(7): 775-782.
[13]	辛雨濛, 卢天公, 孙震晓. 甘草干姜汤对顺铂所致巨噬细胞毒性的保护作用[J]. 中国药物警戒, 2023, 20(6): 661-670.
[14]	赵荣华, 孙静, 包蕾, 耿子涵, 李贵平, 王道涵, 李舒冉, 张敬升, 庞博, 徐英莉, 周利润, 鲍岩岩, 陈梦苹, 郭姗姗, 崔晓兰. 金振口服液对人冠状病毒肺炎热毒疫幼龄小鼠模型的干预机制[J]. 中国药物警戒, 2023, 20(3): 248-252.
[15]	何慧, 柴媛媛, 徐云霞, 俞沁玮, 黄鑫, 张陆勇, 江振洲. 基于LC-MS/MS同时测定小鼠血浆中对乙酰氨基酚及其毒性代谢产物对乙酰氨基酚半胱氨酸的浓度[J]. 中国药物警戒, 2023, 20(3): 266-272.